LOUISVILLE, Colo.–(BUSINESS WIRE)–Biodesix, Inc. (Nasdaq: BDSX), a leader in lung disease diagnostics, will announce its financial results for Q3 2024 before trading starts on November 1. A conference call and webcast to discuss these results will take place at 8:30 a.m. Eastern Time on the same day.
To register for the webcast, click here. Analysts wanting to participate in the Q&A session should use this link. A replay will be available on Biodesix’s investor website two hours after the call. Participants should join 15 minutes early.
About Biodesix: Biodesix offers five Medicare-covered tests for lung diseases. Its Nodify Lung® test assesses the malignancy risk of lung nodules, helping physicians make informed decisions. The IQLung™ test portfolio aids lung cancer patients with treatment decisions. Biodesix also partners with top biopharmaceutical companies for biomarker discovery and clinical trial support. Visit biodesix.com for more information.
Forward-Looking Statements: This announcement may contain forward-looking statements that carry risks and uncertainties. Actual results may differ due to various factors. For more details, see the Risk Factors in Biodesix’s latest annual report on Form 10-K filed on March 1, 2024.
Contact Information:
Media:
Natalie St. Denis
Email: Natalie.StDenis@biodesix.com
Phone: 1-720-925-9285
Investors:
Chris Brinzey
Email: chris.brinzey@westwicke.com
Phone: (339) 970-2843
Source: Biodesix, Inc.
`
